• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, April 30

Dr Reddy's Laboratories Ltd on Monday launched Redituxa, its brand of rituximab, a monoclonal antibody (MAb) used in the treatment of Non-Hodgkin's Lymphoma (NHL). The drug was launched in the presence of over 100 oncologists, followed by a technical session on the development of the drug, according to a release. Redituxa is the second product from Dr Reddy's biologics division. The company has also launched a social initiative — Sparsh — an assistance program for cancer patients undergoing treatment. The needy patients identified by the doctors through Sparsh would be provided Redituxa free of cost.

More Stories on : Announcements | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Addison shifts plants, warehouse from Chennai to new facility

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line